Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of chronic osteoarthritis of the hip or knee for 1 year or longer.~* an average pain due to osteoarthritis of moderate, moderately-severe, or severe for the 14 days prior to enrollment.~Exclusion Criteria:~* ingest opioid analgesics on a daily basis.~* ingest \>2500 milligrams (mg) acetaminophen on a daily basis.~* require \<20 mg or \>80 mg of morphine (or opioid equivalents) per day for control of their osteoarthritis pain.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BTDS (Type: EXPERIMENTAL): Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match BTDS 5, 10 or 20 mcg/h

Based on this trial design, predict the completion outcome and termination type (if applicable).